TC99M nofetumomab merpentan
Trade name: Verluma
mAbapprovedImaging agent
Approved
Aug 20, 1996
Technetium (99mTc) nofetumomab merpentan is a mouse monoclonal antibody derivative used in the diagnosis of lung cancer, gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma. The antibody part, nofetumomab, is attached to the chelator merpentan, which links it to the radioisotope technetium-99m (99mTc). — Wikipedia
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1990s
- Aug 20, 1996
Earliest FDA Approval
- Oct 13, 1998
Boehringer Ingelheim — First NDA Organization
- Oct 13, 1998
Boehringer Ingelheim — NDA Secondary Org
- Oct 13, 1998
Boehringer Ingelheim — NDA Organization
Indications
Approved for
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
- Unspecified targetOTHER
Diagnostic agent
- Epithelial cell adhesion moleculeImmunity, passive
EPCAM immunity, passive
Approval history
- approvedAug 20, 1996
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
- Imaging
- 99-Technetium
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaTechnetium (99mTc) nofetumomab merpentan ↗
- ChEMBLCHEMBL2109287 ↗
Also known as
- nofetumomab
- nofetumomab
- nofetumomab
- nofetumomab merpentan 99tc
- nr-lu-10
- tc-99m-nofetumomab merpentan
- tc-99m-nofetumomab merpentan
- tc-99m-nofetumomab merpentan
- tc-99m-nofetumomab merpentan
- tc-99m nofetumomab merpentan nr-lu-10
- technetium (99mtc) nofetumomab merpentan
- technetium (99mtc) nofetumomab merpentan
- technetium (99mtc) nofetumomab merpentan
- technetium tc 99m nofetumomab merpentan
- technetium tc 99m nofetumomab merpentan
- technetium tc 99m nofetumomab merpentan
- technetium tc 99m-nofetumomab merpentan
- technetium tc-99m nofetumomab merpentan
- verluma
- verluma
- verluma
- verluma
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Boehringer Ingelheim | For profit | NDA2 | Oct 13, 1998 |
| Boehringer Ingelheim | For profit | NDA | Oct 13, 1998 |